Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Revenue (2016 - 2023)

RedHill Biopharma has reported Revenue over the past 12 years, most recently at $1.8 million for Q2 2023.

  • Quarterly Revenue fell 90.21% to $1.8 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $35.7 million through Jun 2023, down 52.42% year-over-year, with the annual reading at $286000.0 for FY2025, 96.44% down from the prior year.
  • Revenue was $1.8 million for Q2 2023 at RedHill Biopharma, down from $3.6 million in the prior quarter.
  • Over five years, Revenue peaked at $22.1 million in Q4 2021 and troughed at $1.1 million in Q1 2020.
  • The 5-year median for Revenue is $15.3 million (2022), against an average of $12.4 million.
  • Year-over-year, Revenue skyrocketed 1848.39% in 2021 and then tumbled 90.21% in 2023.
  • A 5-year view of Revenue shows it stood at $1.6 million in 2019, then surged by 1249.75% to $21.5 million in 2020, then rose by 2.84% to $22.1 million in 2021, then plummeted by 42.01% to $12.8 million in 2022, then crashed by 85.97% to $1.8 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Revenue are $1.8 million (Q2 2023), $3.6 million (Q1 2023), and $12.8 million (Q4 2022).